This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
During the last decade there has been a tremendous resurgence of interest in the etiology of Parkinson's disease (PD), despite the fact that there is, as yet, no direct evidence as to its cause. Nonetheless, most of those working in the field remain undaunted, proceeding full steam ahead to take advantage of the clues and leads that now seem so plentiful. While much of the original stimulus for this "etiological renaissance" stems from the discovery of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a simple pyridine moiety that is selectively toxic to the dopaminergic neurons of the substantia nigra, the research on the cause of PD has taken on a life of its own. Avenues of investigation range from the newly evolving field of molecular epidemiology to neurochemical studies of nitric oxide, gas that is also a neurotransmitter, and perhaps a killer of nerve cells.
In this article, some of the history that has gotten us to this point will be reviewed, with a particular emphasis on the MPTP story. Where appropriate, future research directions will be sketched out. At the same time however, one of the broader purposes of this article is to perform what might be called a "reality check" on current research, by providing a gentle reminder of the many phenomena that must be explained by any etiologic hypothesis which is to be seriously considered.
Background and history.
Interest in the cause of PD has waxed and waned throughout this century. One of the peaks almost certainly occurred with the advent of postencephalitic parkinsonism, which enhanced interest in the syndrome not only because of its widespread appearance after the great pandemic of 1918 to 1920, but also because it appeared to hold clues to the cause of the disease, since the syndrome so clearly followed an encephalitic illness. While it is now clear that postencephalitic …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
